Literature DB >> 15346240

The natural history of hepatitis C.

Nezam H Afdhal1.   

Abstract

Hepatitis C virus (HCV) is the most common cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) in the United States and infects an estimated 170 million people worldwide. In the United States, overall hepatitis C prevalence is 1.8% and is higher in African Americans and Hispanics than it is in white Americans. The age distribution places 65% of all subjects with anti-HCV antibodies between 30 and 49 years of age. Before serological screening of blood products was initiated, hepatitis C was most commonly transmitted by transfusion of contaminated blood products, but now it is acquired primarily via intravenous drug use. Only 10 to 25% of infected adult patients spontaneously resolve their infection, and the remaining 75% remain persistently viremic and often asymptomatic. Progression of liver disease in 20 to 30% of patients can lead to compensated and eventually decompensated cirrhosis or hepatocellular carcinoma, or both. This article looks briefly at the epidemiology and natural history of hepatitis C.

Entities:  

Mesh:

Year:  2004        PMID: 15346240     DOI: 10.1055/s-2004-832922

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  71 in total

1.  Non-invasive assessment of fibrosis using color Doppler ultrasound in patients with hepatitis C virus in the Amazon rainforest, Brazil.

Authors:  Jorge Leão; Marianna Brock; Márcia Castilho; André Scariot; Ana Scariot; Wornei Braga
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

3.  Chemokine antagonism in chronic hepatitis C virus infection.

Authors:  Edgar D Charles; Lynn B Dustin
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 4.  Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.

Authors:  Nobuko Taguchi; Shinya Ito
Journal:  Can Fam Physician       Date:  2005-12       Impact factor: 3.275

5.  Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center.

Authors:  Varun Gupta; Ashish Kumar; Praveen Sharma; Naresh Bansal; Vikas Singla; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2015-05-21

6.  Statistical linkage analysis of substitutions in patient-derived sequences of genotype 1a hepatitis C virus nonstructural protein 3 exposes targets for immunogen design.

Authors:  Ahmed A Quadeer; Raymond H Y Louie; Karthik Shekhar; Arup K Chakraborty; I-Ming Hsing; Matthew R McKay
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

Review 7.  Hepatitis C in hemodialysis patients.

Authors:  Smaragdi Marinaki; John N Boletis; Stratigoula Sakellariou; Ioanna K Delladetsima
Journal:  World J Hepatol       Date:  2015-03-27

Review 8.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

9.  Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial.

Authors:  G T Everson; M L Shiffman; J C Hoefs; T R Morgan; R K Sterling; D A Wagner; J L Desanto; T M Curto; E C Wright
Journal:  Aliment Pharmacol Ther       Date:  2008-12-01       Impact factor: 8.171

10.  Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation.

Authors:  Ming-Ling Chang; Chau-Ting Yeh; Deng-Yn Lin; Yu-Pin Ho; Chen-Ming Hsu; D Montgomery Bissell
Journal:  BMC Med Genomics       Date:  2009-08-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.